Trial
NCT03401853
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
Merck Sharp & Dohme LLC
Condition
Recurrent Diffuse Large B-Cell Lymphoma
Intervention
Laboratory Biomarker Analysis
Why stopped
Study terminated to end of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-22